Assenagon Asset Management
UTHR icon

Assenagon Asset Management’s United Therapeutics UTHR Stock Holding History

Assenagon Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.8M Buy
84,538
+37,355
+79% +$21M 0.06% 246
2026
Q1 		$28M Buy
47,183
+22,555
+92% +$11.2M 0.04% 284
2025
Q4 		$12M Buy
24,628
+3,824
+18% +$1.78M 0.02% 470
2025
Q3 		$8.72M Sell
20,804
-13,202
-39% -$4.44M 0.01% 514
2025
Q2 		$9.77M Sell
34,006
-31,399
-48% -$9.38M 0.01% 467
2025
Q1 		$20.2M Buy
65,405
+10,290
+19% +$3.53M 0.03% 327
2024
Q4 		$19.4M Sell
55,115
-8,067
-13% -$2.97M 0.03% 362
2024
Q3 		$22.6M Sell
63,182
-27,398
-30% -$9.25M 0.04% 311
2024
Q2 		$28.9M Buy
90,580
+9,673
+12% +$2.56M 0.06% 224
2024
Q1 		$18.6M Buy
80,907
+2,905
+4% +$656K 0.04% 298
2023
Q4 		$17.2M Sell
78,002
-11,131
-12% -$2.57M 0.05% 325
2023
Q3 		$20.1M Sell
89,133
-399,050
-82% -$91.9M 0.06% 250
2023
Q2 		$108M Sell
488,183
-177,385
-27% -$39.3M 0.37% 47
2023
Q1 		$149M Buy
665,568
+63,814
+11% +$15.7M 0.53% 37
2022
Q4 		$167M Sell
601,754
-11,530
-2% -$2.91M 0.6% 30
2022
Q3 		$128M Sell
613,284
-28,372
-4% -$6.34M 0.49% 42
2022
Q2 		$151M Buy
641,656
+431,739
+206% +$87.8M 0.56% 31
2022
Q1 		$37.7M Buy
209,917
+198,673
+1,767% +$37.8M 0.1% 165
2021
Q4 		$2.43M Sell
11,244
-32,984
-75% -$6.48M 0.01% 749
2021
Q3 		$8.16M Sell
44,228
-334,728
-88% -$65.9M 0.03% 318
2021
Q2 		$68M Buy
378,956
+220,777
+140% +$42M 0.23% 80
2021
Q1 		$26.5M Buy
+158,179
New +$26.4M 0.11% 166
2020
Q4 		– Sell
-8,714
Closed -$880K – 1276
2020
Q3 		$880K Sell
8,714
-18,854
-68% -$2.07M ﹤0.01% 868
2020
Q2 		$3.34M Buy
+27,568
New +$3.1M 0.02% 436
2019
Q3 		– Sell
-35,762
Closed -$2.79M – 1086
2019
Q2 		$2.79M Buy
35,762
+5,315
+17% +$497K 0.02% 432
2019
Q1 		$3.57M Buy
30,447
+3,469
+13% +$404K 0.03% 373
2018
Q4 		$2.94M Buy
26,978
+8,542
+46% +$990K 0.03% 346
2018
Q3 		$2.36M Buy
18,436
+4,080
+28% +$505K 0.02% 485
2018
Q2 		$1.62M Buy
14,356
+7,116
+98% +$782K 0.02% 357
2018
Q1 		$813K Sell
7,240
-141
-2% -$17.9K 0.01% 428
2017
Q4 		$1.09M Sell
7,381
-1,883
-20% -$239K 0.01% 530
2017
Q3 		$1.09M Buy
9,264
+5,982
+182% +$764K 0.01% 371
2017
Q2 		$426K Buy
+3,282
New +$409K 0.01% 207

Other funds holding UTHR

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AIM
Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Assenagon Asset Management's UTHR Position: Q2 2026 in Review

Assenagon Asset Management increased its United Therapeutics (UTHR) stake by 79% in Q2 2026, buying an estimated $21M and bringing the position to 84,538 shares worth $45.8M. The position accounts for 0.06% of the portfolio, ranked #246.

Assenagon Asset Management first reported a position in UTHR in Q2 2017 and has held it in 33 quarters since. The position peaked at $167M in Q4 2022. 122 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Assenagon Asset Management held 84,538 shares of United Therapeutics worth $45.8M as of Q2 2026.
  • Assenagon Asset Management bought 37,355 United Therapeutics shares in Q2 2026, an estimated $21M.
  • United Therapeutics made up 0.06% of Assenagon Asset Management's portfolio in Q2 2026, its #246 holding.
  • Assenagon Asset Management first reported a position in United Therapeutics in Q2 2017 and has held it in 33 quarters since.
  • Assenagon Asset Management's United Therapeutics position peaked at $167M in Q4 2022.
  • 122 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.